Pin your most used calculators here by clicking the star in the dropdown.
Khorana Score (VTE Risk)
Clinical Context & Background
The Khorana Score stratifies cancer patients into risk groups for developing venous thromboembolism (VTE) prior to starting chemotherapy. It helps identify patients who might benefit from thromboprophylaxis. Recent guidelines (ASCO 2023) continue to endorse its use for risk assessment.
Formula Logic
Sum points based on cancer site, platelet count, Hb/ESA use, WBC count, and BMI.Reference Data
| Risk Group | Score | VTE Risk Rate |
|---|---|---|
| Low Risk | 0 | 0.8% - 3.0% |
| Intermediate Risk | 1 - 2 | 1.8% - 8.4% |
| High Risk | ≥ 3 | 7.1% - 12.9% |
Evidence-based oncology decision support. Verify with clinical guidelines.